Currently, there are only two therapeutic tumor vaccines – sipuleucel-T for melanoma and Bacillus Calmette-Guérin (BCG) for bladder cancer, as well as prophylactic tumor vaccines against human papillomavirus infection and hepatitis B infection approved by the US Food and Drug Administration (FDA). . Recently, several other tumor vaccines have entered clinical development and evidence of efficacy has begun to emerge.
According to Mordor Intelligence, the global vaccine market size was $6.79 billion in 2021 and will increase at a compound annual growth rate of 11.53% from 2022 to 2026. The expected market size by 2026 will be approximately 12 billion US dollars.
Currently, the design and preclinical development process for tumor vaccines is complex and lengthy, hindering the efficiency and success rate of tumor vaccine research and development.
Incorporating XtalPi’s industry expertise in AI computing and robotic automation, this collaboration aims to build an AI tumor vaccine R&D platform that applies advanced AI algorithms and high-precision molecular modeling to predict and design various tumor vaccines that can activate specific immune responses for to kill tumors The tumor vaccines will be screened and verified through automated experiments, and by integrating algorithmic feedback to optimize performance and efficacy, the platform is expected to generate preclinical tumor vaccine compounds with robust immune activity.
Dr. Shuhao Wenco-founder and president of XtalPi, comments: “As a company headquartered in the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone, XtalPi is committed to realizing the synergies between Shenzhen and Hong Kong creating a new paradigm for innovation in the Greater Bay Area. Empowered by the latest technological advances in automation, artificial intelligence is accelerating more innovative and diverse areas in drug research and development. Together with CK Life Sciences, we are committed to overcoming conventional limitations and discovering various applications for cutting-edge technologies. We believe that the AI cancer vaccine platform jointly developed by CK Life Sciences and XtalPi will inspire the global scientific community to advance vaccine research and development and accelerate key development milestones for cancer vaccines. We are confident that this collaboration will significantly facilitate scientific research exchange in the Greater Bay Area.”
Dr. Melvin TohVice President and Chief Scientific Officer of CK Life Sciences, comments: “The R&D of tumor vaccines is one of the key development directions of CK Life Sciences. The collaboration with XtalPi will apply XtalPi’s AI algorithm, molecular modeling and automated experiments to accelerate the R&D -process, improve the success rate, and increase the effectiveness of tumor vaccines.”
Founded in 2014, XtalPi founders recognized a common hurdle in drug development related to solid polymorphism that could be successfully addressed by quantum physics predictions. Since then, XtalPi has maintained its focus on identifying and then attacking traditional bottlenecks in biopharma R&D with innovative technologies. Through significant capital investments in automation and personnel, XtalPi now has four locations worldwide and employs approximately 1,000 employees. XtalPi has engaged in collaborative research with almost all of the top 20 pharmaceutical companies in the world. Its ID4 platform combines physics-based simulations with experimental validation and refinement, automation for rapid synthesis, and machine learning to continuously improve prediction accuracy and process efficiency.
About CK Life Sciences
CK Life Sciences (stock code: 0775) is listed on the Stock Exchange of Hong Kong. Having the mission to improve the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialization, marketing, sale of and investment in products and assets that fall into three core categories – nutraceuticals, pharmaceuticals and agriculture-related. CK Life Sciences is a member of the CK Hutchison Group.
SOURCE XtalPi Inc.